Rate My Professor Johannes Fruehauf

Fruehauf's research specializations include RNAi therapeutics, bacterial-mediated gene silencing, and cancer biology. He has authored over 20 peer-reviewed publications and is named inventor on nine patents related to RNAi and bacterial therapeutics. Notable publications encompass 'Short hairpin RNA–expressing bacteria elicit RNA interference in mammals' (Nature Biotechnology, 2006), 'Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs in prostate cancer cells' (PNAS, 2012), 'GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth' (Cancer Research, 2012), and contributions to siRNA design and avian influenza virus inhibition. His career history features key roles in biotechnology startups: Head of R&D at Cequent Pharmaceuticals, where he invented transkingdom RNAi (tkRNAi) technology and led IND filings; co-founder of ViThera Pharmaceuticals focused on engineered probiotics; founder of Cambridge BioLabs for concept validation; and co-founder of LabCentral in 2013, a shared lab facility in Kendall Square that has incubated over 500 biotech startups, fostering Cambridge's biotech ecosystem. He also founded BioLabs, an international network of biotech coworking spaces, and Mission BioCapital. Fruehauf instructs in MIT Professional Education programs on innovation, organizations, and technology, contributing to academic and entrepreneurial training.